Information Provided By:
Fly News Breaks for December 7, 2015
OPHT
Dec 7, 2015 | 07:31 EDT
Citi analyst Yigal Nochomovitz says newly released data suggest Ophthotech's Fovista may offer an "unprecedented level of efficacy" in hard-to-treat wet AMD. Noting that the drug could eventually see deeper adoption across multiple lines of therapy, Nochomovitz increased his estimate for peak Fovista revenues to $3.1B from $2.5B and raised his price target on Ophthotech to $128 from $102.
News For OPHT From the Last 2 Days
There are no results for your query OPHT